This is a working overview of thymosin beta-4 fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
== Biography and education == Saladino earned a chemistry degree from the College of William and Mary, followed by 6 years spent traveling in North America and New Zealand. He later became a physician assistant and later did training in cardiology, gaining his MD from the University of Arizona in 2015, and completing his residency at the University of Washington in 2019. Saladino has board certification in psychiatry and is a certified "Functional Medicine" practitioner. As of 2022, his license to practice medicine in California was "delinquent" due to not paying fees.
Approximately 20–25% of the world's adults have metabolic syndrome. In 2000, ~32% of U.S. adults met criteria; more recent estimates are ~34%. In young children, there is no consensus on measurement; age-specific cut points are not well established. Continuous risk scores are often used instead. Microbiome composition and some conditions have been associated with metabolic syndrome, sometimes with gender-specific patterns.
A drop in progesterone levels is possibly one step in the onset of labor. In addition, progesterone inhibits lactation during pregnancy. The fall in progesterone levels following delivery is one of the triggers for milk production. The fetus metabolizes placental progesterone in the production of adrenal steroids.
== Process == The first step of the PEGylation is the suitable functionalization of the PEG polymer at one or both ends. PEGs that are activated at each end with the same reactive moiety are known as "homobifunctional", whereas if the functional groups present are different, then the PEG derivative is referred as "heterobifunctional" or "heterofunctional". The chemically active or activated derivatives of the PEG polymer are prepared to attach the PEG to the desired molecule. The overall PEGylation processes used to date for protein conjugation can be broadly classified into two types, namely a solution phase batch process and an on-column fed-batch process. The simple and commonly adopted batch process involves the mixing of reagents together in a suitable buffer solution, preferably at a temperature between 4 and 6 °C, followed by the separation and purification of the desired product using a suitable technique based on its physicochemical properties, including size exclusion chromatography (SEC), ion exchange chromatography (IEX), hydrophobic interaction chromatography (HIC) and membranes or aqueous two-phase systems (ATPS). The choice of the suitable functional group for the PEG derivative is based on the type of available reactive group on the molecule that will be coupled to the PEG. For proteins, typical reactive amino acids include lysine, cysteine, histidine, arginine, aspartic acid, glutamic acid, serine, threonine and tyrosine.
In food animals such as chickens, rabbits and pigs, some harmless strains of B. cereus are used as a probiotic feed additive to reduce Salmonella in the animals' intestines and cecum. This improves the animals' growth, as well as food safety for humans who eat them. In addition, B. cereus create and release enzymes that aid in the digestion of materials that are typically difficult to digest, such as woody plant matter, in the guts of other organisms. The strain B. cereus B25 is a biofungicide. A study by Figueroa-López et al. showed that the presence of this strain reduced Fusarium verticillioides growth. B25 shows promise for reduction of mycotoxin concentrations in grains.
Sources: en.wikipedia.org
GLP-1 Formula – a formulation intended to support endogenous glucagon-like peptide-1 (GLP-1) activity. The GLP-1 Formula is a proprietary blend of plant extracts, probiotics, and prebiotics developed to support endogenous glucagon-like peptide-1 (GLP-1) activity. GLP-1 is a hormone secreted by intestinal L-cells in response to food intake that regulates insulin secretion, suppresses glucagon release, reduces appetite, and slows gastric emptying. TCI leveraged its Bio-Resource Data Mining technology to identify natural active compounds, and subsequently developed the formula through in-vitro validations and human trials. In-vitro studies indicated that the formula stimulates natural GLP-1 secretion from intestinal L-cells, which TCI reported to support stable blood glucose levels, enhances fat metabolism, and may induce white fat browning. SugarLock – a botanical extract designed to modulate postprandial glucose response. It is described as a proprietary, polyphenol-rich, allergen-free extract, and in clinical evaluation over a six-week intervention period was shown to support fasting blood glucose, decrease body fat, and attenuate postprandial blood sugar spikes. Outcomes were further validated through continuous glucose monitoring (CGM). TCI has positioned SugarLock as an ingredient for brands targeting glycemic control and metabolic health applications. The ingredient was featured at SupplySide Global 2025, where TCI's Chief Product Officer presented clinical findings from the intervention study.
=== Vasculitis === A link has been shown between ANCA-associated vasculitis and SNPs in the COL11A2 gene in a Genomewide Association Study. It is proposed that this association may be due to linkage disequilibrium between a SNP in the HLA-DP locus and SNPs in COL11A2. This is theorised as the SNP in the HLA molecule was found to be very strongly associated with these diseases with evidence for a single genetic association.
== Metal sulfides == Sulfur reacts with many metals. Electropositive metals give polysulfide salts. Copper, zinc and silver are tarnished by sulfur. Although many metal sulfides are known, most are prepared by high temperature reactions of the elements. Sulfide minerals contain the sulfide (S2-) or disulfide (S22-) anions. Typical examples are:
== Clinical pharmacology == Although the drugs omeprazole, lansoprazole, pantoprazole, and rabeprazole share common structure and mode of action, each differs somewhat in its clinical pharmacology. Differing pyridine and benzimidazole substituents result in small, but potentially significant different physical and chemical properties. Direct comparison of pantoprazole sodium with other anti-secretory drugs showed that it was significantly more effective than H2-receptor antagonists and either equivalent or better than other clinically used PPIs. Another study states rabeprazole undergoes activation over a greater pH range than omeprazole, lansoprazole, and pantoprazole, and converts to the sulphenamide form more rapidly than any of these three drugs. Most oral PPI preparations are enteric-coated, due to the rapid degradation of the drugs in the acidic conditions of the stomach. For example omeprazole is unstable in acid with a half-life of 2 min at pH 1–3, but is significantly more stable at pH 7 (half-life ca. 20 h). The acid protective coating prevents conversion to the active principle in the lumen of the stomach, which then will react with any available sulfhydryl group in food and will not penetrate to the lumen of the secretory canaliculus The oral bioavailability of PPIs is high; 77% for pantoprazole, 80–90% for lansoprazole and 89% for esomeprazole. All the PPIs except tenatoprazole are rapidly metabolized in the liver by CYP enzymes, mostly by CYP2C19 and CYP3A4. PPIs are sensitive to CYP enzymes and have different pharmacokinetic profiles.
Sources: en.wikipedia.org
== Abstracting and indexing == This journal is abstracted and indexed in BIOSIS, Chemical Abstracts, Clinical Chemistry Lookout, Current Clinical Chemistry, Current Contents/Life Sciences, EMBASE, EMBiology, FRANCIS, Index Chemica, Informedicus, MEDLINE, PASCAL, Reference Update, and Scopus.
=== Biotin === Subsequently, with Vincent du Vigneaud, he used the newly developed technique of chromatography that he had learned while a student in Zürich, to isolate and then crystallize biotin. This work began a theme that continued throughout his career of determining the importance of sulfur in biologically active structures. He applied this to peptides as well.
While SR-17018 produced little to no analgesic tolerance in the hot plate test, subsequent research using other rodent pain models found that it did produce tolerance in the warm water tail immersion assay and to a similar degree as morphine and oxycodone. Moreover, both SR-17018 and morphine showed cross-tolerance with each other in this test. Both morphine and SR-17018 tolerance in the test could be partially reversed by a protein kinase C (PKC) inhibitor. Based on these findings, it was concluded that a single analgesic test may be inadequate for assessing a drug's analgesic tolerance. However, a later study found that SR-17018 produced analgesic tolerance, albeit slightly delayed, in the hot plate test as well. In addition to the preceding findings, whereas SR-17018 reversed morphine analgesic tolerance in the hot plate test, it did not do so in the tail flick assay. On the other hand, chronic SR-17018 administration maintained efficacy in the formalin paw-withdrawal assay and paclitaxel-induced neuropathic pain model, showing no tolerance in these tests, whereas morphine and oxycodone caused tolerance in these assays. In a subsequent study to its initial in-vitro characterization, it was found that SR-17018 showed low activational efficacy across a selection of MOR signaling pathways, whereas classical opioids like morphine, fentanyl, methadone, and oxycodone showed higher efficacy.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.